Under the agreement, Samsung Biologics will offer a wide range of services from cell line development, process development, non-clinical and clinical equipment manufacturing to IND submission for STCube.
STCube is a biopharmaceutical company focused on innovation which develops revolutionary anticancer therapies thanks to its cutting-edge research. STCube has decided to establish a strategic partnership with Samsung Biologics based on the rapid growth of the company’s development and manufacturing capabilities and a solid positioning in the world market as a world class CDO. The two companies took an agile step towards an agreement because it only took two weeks between the initial discussion phase and the conclusion of the contract.
The antibody STT-003, developed by the American research center of STCube located in Maryland, was the subject of a material transfer agreement (MTA) between STCube and a multinational pharmaceutical company.
A new STT-003 immune checkpoint is found to be widely expressed on the surfaces of immune and cancer cells, suppressing their immune functions. Partly because of this high expression of STT-003 in various cancer cells, therapies targeting STT-003 are expected to exhibit more favorable anticancer effects than conventional PD-1 / PD-L1 therapies.
STCube plans to submit an IND on its antibody STT-003 in 2021, both for use in monotherapy and for use in combination therapy. Clinical trials are currently planned in major medical institutions in the United States.
“We have signed a contract with Samsung Biologics, a global company of CMO, CDO and CRO, to produce the first STT-003 antibody in its class, laying the foundation for a stable implementation of global clinical trials,” said Hyun-Jin Jung, Chief Executive Officer, STCube. “To date, several internationally recognized immunologists have agreed to serve on the Scientific Advisory Committee for Phase I clinical studies of STT-003 antibodies, including the head of clinical research at a leading clinical institution for treatment cancer. “
Tae Han Kim, CEO of Samsung Biologics, said: “We are proud to contribute to the development of this exciting new target cancer drug candidate through our ongoing partnership. As a global partner of CMOs, CDOs and CROs, we will continue to provide faster and better service to our customers for maximum customer satisfaction thanks to Samsung’s competitive advantages: a faster schedule, excellent quality and exceptional capabilities. ”
Under the agreement, Samsung Biologics will offer a wide range of services from cell line development, process development, non-clinical and clinical equipment manufacturing to IND submission for STCube.
STCube is a biopharmaceutical company focused on innovation which develops revolutionary anticancer therapies thanks to its cutting-edge research. STCube has decided to establish a strategic partnership with Samsung Biologics based on the rapid growth of the company’s development and manufacturing capabilities and a solid positioning in the world market as a world class CDO. The two companies took an agile step towards an agreement because it only took two weeks between the initial discussion phase and the conclusion of the contract.
The antibody STT-003, developed by the American research center of STCube located in Maryland, was the subject of a material transfer agreement (MTA) between STCube and a multinational pharmaceutical company.
A new STT-003 immune checkpoint is found to be widely expressed on the surfaces of immune and cancer cells, suppressing their immune functions. Partly because of this high expression of STT-003 in various cancer cells, therapies targeting STT-003 are expected to exhibit more favorable anticancer effects than conventional PD-1 / PD-L1 therapies.
STCube plans to submit an IND on its antibody STT-003 in 2021, both for use in monotherapy and for use in combination therapy. Clinical trials are currently planned in major medical institutions in the United States.
“We have signed a contract with Samsung Biologics, a global company of CMO, CDO and CRO, to produce the first STT-003 antibody in its class, laying the foundation for a stable implementation of global clinical trials,” said Hyun-Jin Jung, Chief Executive Officer, STCube. “To date, several internationally recognized immunologists have agreed to serve on the Scientific Advisory Committee for Phase I clinical studies of STT-003 antibodies, including the head of clinical research at a leading clinical institution for treatment cancer. “
Tae Han Kim, CEO of Samsung Biologics, said: “We are proud to contribute to the development of this exciting new target cancer drug candidate through our ongoing partnership. As a global partner of CMOs, CDOs and CROs, we will continue to provide faster and better service to our customers for maximum customer satisfaction thanks to Samsung’s competitive advantages: a faster schedule, excellent quality and exceptional capabilities. ”
